Last reviewed · How we verify
NCT06972160
Intervention Project to Increase Adherence to Colorectal Cancer Screening in Barcelos/Esposende
NA trial testing Arm1: intervention 1 (SMS+call) in Colon and Rectal Cancer in 1,038 participants. Currently enrolling.
30 September 2025
Quick facts
| Lead sponsor | Local Health Unit Barcelos/Esposende, Public Health Unit |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 1,038 |
| Start date | 1 April 2025 |
| Primary completion | 30 September 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Portugal |
Drugs / interventions tested
- Arm1: intervention 1 (SMS+call)
- Control group — full drug profile →
Conditions studied
- Colon and Rectal Cancer — all drugs for Colon and Rectal Cancer →
Sponsor
Local Health Unit Barcelos/Esposende, Public Health Unit
Who can join
Adults 49 to 75, any sex, with Colon and Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An experimental study through a randomized clinical trial, without blinding (for participants and the research team), with a control group (not subject to intervention) and an intervention group (subject to two text messages, an automated non-human call or a call made by the administrative assistant, and a phone call made by a physician).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06972160
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06972160 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Local Health Unit Barcelos/Esposende, Public Health Unit
- Last refreshed: 14 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06972160.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing